Principles and application of PET CT & PET MR


Published on

Published in: Health & Medicine, Technology
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Positron•Uses positron(β+) emitting radio-isotopes to label physiologic tracers (e.g. radiopharmaceuticals)•Positrons are unstable in that they annihilate with electrons, resulting in two anti-parallel photons each with energy 511 keV•PET scanners measure coincident annihilation photons and collimate the source of the decay via coincidence detection Emission•The source of the signal is emissionof photons from within the patient, as opposed to photons transmitted through the patient in x-ray imaging (mammography) Tomography•Three-dimensional volume image reconstruction through collection of projection data from all angles around the patient
  • The first approval by CMS for reimbursement was for the evaluation of the solitary pulmonary nodule (SPN) and the initial staging of non–small cell lung cancer (NSCLC), effective January 1, 1998.
  • Annihilation reaction. Positrons ( β+) released from the nucleus of FDG annihilate with electrons ( β−), releasing two coincidence 511-keV photons ( γ), which are detected by scintillation crystals (blue rectangles). N=neutron, P= proton
  • Mci-millicurie., 1mci=1bq,37megabq(Mbq)
  • Initially rod source germanium 68 now ct
  • Radio Nuclide Effective Radiation Dose (mSv) F 18 -FDG (370 MBq) 7.0
  • Photograph (side view) of a hybrid PET-CTscanner shows the PET(P) and CT (C) components. Thedistance between the PETand CT scanners is 80 cm, andthe maximum coverage that can be achieved during acombined study is 145 cm. The PETand CT scanners are mechanically independent and can be used in isolation fo rPET or CT only.
  • Good control of blood glucose is essential because the uptake of FDG into cells is competitively inhibited by glucose , as they use a common transport mechanism (glucose transporters [GLUT]) for facilitated transport into both normal and tumor cells
  • Typical scout image obtained during an FDG PET-CT study. The blue-purple rectangle represents CT coverage during the study, and each overlapping green rectangle represents PET coverage . Six to seven bed positions are required for PET coverage of the neck, chest, abdomen, and pelvis .
  • Patient motion can produce significant artifacts on the fused images and may cause confusion as to the correct position of the origin of the detected photon.
  • First installation of clinical PET/MRI system at University of Tübingen. System is dedicated for brain applications and features 3-T MRI system with dedicated head coil and PET head insert with 18-cm axial field of view. (Courtesy of University of Tübingen.)
  • Philips ..
  • PET/CT and PET/MRI 71-y-old woman with frontobasal meningioma in olfactory region. PET/CT images were acquired 20 min and PET/MR images 100 min after injection of 135 MBq of68 Ga-[1,4,7,10-tetraazacyclododecane-N,N9,N$,N$9-tetraacetic acid]-DPhe1,Tyr3-octreotide. Tracer uptake inthe tumor is seen on PET images. Inaddition, second smaller and previously unknown frontal meningioma was seen on PET and possibly corresponded to small mass demonstrated on T2-weighted turbo spin-echo MR images.This finding was not detected by CT.
  • 2.5 cut off limit for spn . By dukes. Refence hagga . Suv initially knw as standarised uptake ratio. Maximum lesional activity /injection dose/ body weight . Help in distinguishing betwn benign and malignant.
  • In mucinus carcinoma ovary false negative
  • Delete this slide?
  • Reduced neuronal activity in left temporoparietal cortex, representing by green .
  • Principles and application of PET CT & PET MR

    2. 2. INTRODUCTIONINTRODUCTION Cancer is one of leading causes of morbidity and mortality in developed countries. Most radiologic procedures map the anatomy and morphology of tumors with little or no information about their metabolism Positron emission tomography (PET) is a coalition of physics, chemistry, physiology, and medicine united in an effort to measure physiologic parameters noninvasively. Positron Emission Tomography and Computed Tomography / MRI is the combination of functional imaging as well as anatomical imaging.
    3. 3. HistoryHistory  1978 the first commercial PET scanner was introduced  70s and 80s PET was mainly used for research  1990s being used in clinics regularly  First approval in 1998.
    4. 4. PRINCIPLE OF PETPRINCIPLE OF PET  The concept of PET is to radiolabel a bio-compound, inject it into the patient, and then measure its bio-distribution as a function of time to determine physiologic quantities associated with the biocompound.  All PET compounds are radiolabeled with positron-emitting radionuclides.  These radionuclides have decay characteristics that enable localization in the body.  A positron is emitted from the nucleus, travels a short distance, and annihilates with its antiparticle (an electron), which results in two 5 I l-keV photons traveling in opposite directions.  After both photons are detected, the activity is localized somewhere along the line defined by the two detectors.
    5. 5. 2-[F-18]Fluoro-2-Deoxy-D-Glucose (FDG) O H O O H HO F H H H H H CH2 OH 511 keV photon 511 keV photon E = mc2 180o + - UC LA
    6. 6. producing radiotracers Synthesizing radiopharmaceuticals from the tracers administering the radiopharmaceutical to a patient measuring the resulting radioactivity distribution in an organ of interest interpreting activity distribution as a function of physiologic parameters. A PET study consists of
    7. 7. PRODUCTION OF RADIONUCLIDEPRODUCTION OF RADIONUCLIDE PET radionuclides are positron emitters. There are 5 convenient nuclides- HALF LIFE (min) Rubidium- 82 1.23 Fluorine – 18 109 Oxygen- 15 2 Nitrogen- 13 10 Carbon- 11 20 Commonly produced isotopes : “F O N C”
    8. 8. SYNTHESIS OF F-18 &FDGSYNTHESIS OF F-18 &FDG Over 500 PET compounds have been synthesized since 1970. Natural substrates such as amino acids, analogues ,fluorinated glucose &drugs. MC used is a glucose analogue, 2-[F18]fluoro- 2-deoxy-D-glucose (FDG).
    9. 9. Why is 18 F the most used positron emitter? 18F is a small atom. its addition to a molecule does not deform it to the point where it is not recognized by the body anymor has a half-life of 109 minutes. This is long enough to perform a complicated chemistry (labelling) , and to allow transport over some distance. It is also long enough to keep the radiation burden to patient low
    10. 10. USES Fluorodeoxyglucose [18F]-labeled 2-deoxyglucose (FDG) is used in neurology, cardiology and oncology to study glucose metabolism. FDG is potentially useful in differentiating benign from malignant forms of lesions because of the high metabolic activity of many types of aggressive tumors. Oxygen [15O]-labeled water is used to evaluate myocardial oxygen consumption and oxygen extraction fraction. It can also be used to measure tumor necrosis.
    11. 11.  Ammonia [13N]-labeled ammonia can be used to measure blood flow.  Leucine [11C]-labeled methionine and leucine can be used to evaluate amino acid uptake and protein synthesis, providing an indicator of tumor viability.  Fluorine Ion Radiolabeled fluorine ion [18F-] was once a standard agent for clinical bone scanning.
    12. 12. A typical production schedule for FDG is 3hours in duration, starting from the time the chemist walks into the laboratory until the radiochemical is produced. The synthesis is 50%-60% efficient, so accounting for this and the radioactive decay, about 200 mCi (7.4 GBq) of FDG is available at the end of the synthesis.
    13. 13. A patient usually receivesA patient usually receives 10 mCi (370 MBq). If two scanners are available so that a patient can receive an injectionIf two scanners are available so that a patient can receive an injection every half hour,every half hour, one production run will allow scanning aboutrun will allow scanning about six patients per day..
    14. 14. Principle of metabolic imaging with FDG Glucose 18 FDG Blood vessel Cell Glucose 6 Phosphate 18FDG 6 Phosphate Fructose 6 Phosphate Pyruvate Anaerobic resp Citric acid cycle G LUT
    15. 15. SCANNER DESIGNSCANNER DESIGN A positron emission tomography (PET) scanner is a large machine with a round, doughnut shaped hole in the middle  Within this machine are multiple rings of detectors that record the emission of energy from the radiotracer in your body. A nearby computer aids in creating the images from the data obtained by the camera or scanner.
    16. 16. SCANNER DESIGN….SCANNER DESIGN…. Detectors are 18-40 rings of crystals forming a cylindrical field of view about 15cm long that can acquire many slices of coincidence data PET scanners use crystals with higher density & higher Z numbers due to sensitivity Group of crystals is put together into a block Four PMT’s to each block of crystal Use “electronic collimation” to detect location of annihilation event
    17. 17. SCANNER DESIGN….SCANNER DESIGN….  Localizing the site of impact is achieved by measuring the light detected in each PMT  Signal is then amplified  System must be able to determine which signals come from paired 511keV photons and record the time of detection (timing discriminator)  Coincidence circuit then examines signals to confirm it if it occurred with in the time window
    18. 18. CRYSTALS USED IN PETCRYSTALS USED IN PET BaFBaF22– Barium Flouride(0.8ns) BGOBGO – Bismuth Germinate Oxide(300ns) LSOLSO – Lutetium Orthosilicate(40ns) GSOGSO – Gadolineum Orthosilicate(60ns) YLSOYLSO – Yttrium Lutetium Orthosilicate(40ns)
    19. 19. COINCIDENCE DETECTIONCOINCIDENCE DETECTION Photons should arrive with in a certain time of one another A coincidence timing window allows detection of the PMT electrical signal from photon pair (4-12ns) If it falls within timing window it is registered as a true event When two different annihilation events are detected with in the timing window is known as “random event”
    20. 20. DATA ACQUSITIONDATA ACQUSITION The detection of photon pairs by opposing crystals create one event (LOR) Millions of these event will be stored with in sinograms and used to reconstruct the image Spatial resolution is determined by the size of crystal and their separation and is typically 3- 5mm PET is 50-100 times more sensitive and produces higher quality than a SPECT Reconstruction is similar to SPECT
    21. 21. RECONSTRUCTIONRECONSTRUCTION PET reconstruction can be performed with a variety of algorithms o Filtered back projection o Iterative reconstruction(ordered subset reconstruction )
    22. 22. ATTENUATION CORRECTIONATTENUATION CORRECTION  Mathematical attenuation correction techniques may be used if tissue attenuation is the same at all areas within a transaxial slice .  Measured attenuation may be performed by two methods: – Transmission scan using a radioactive source rotating it around the patient – CT scan to measure tissue density  The ability to correct for attenuation improves quality and permits absolute quantification of radioactivity in the body
    23. 23. Resolution in PET is determined by three factors: distance the positron travels before it annihilates with an electron, variation in angle between the two annihilation photons, and physical size of the detectors. A positron will travel between 0.5 and 2 mm in tissue before annihilation, depending on its energy. Typical detector sizes are 1 -3 mm. The best possible resolution of a PET scanner is 1-2mm. Typical clinical scanners have a resolution of approximately 4-7 mm.
    24. 24. PET vs. CT & MRIPET vs. CT & MRI PET CT and MRI Shows extent of disease Detects changes in body structure Can help in monitoring treatment and shows it’s effectiveness Simply confirms the presence of a mass Reveals disease earlier, can diagnose faster Can detect whether a mass is benign of malignant Can detect abnomalities before there is an anatomical change
    25. 25. SAFETY ASPECTS OF PETSAFETY ASPECTS OF PET  PET has 511Kev gamma rays energy, that is 3 times of 140Kev gamma ray energy of Technitium99m  Due to their high energy 16 times more lead is required to obtain the same stopping effect for 511Kev photons as compared to 140Kev photons
    26. 26. SAFETY ASPECTS OF PETSAFETY ASPECTS OF PET So Tungsten shielding is used for Positron emitting radionuclide. It provides 1.4 times the shielding capability for the same thickness of Lead
    27. 27. CONTRA INDICATIONSCONTRA INDICATIONS Pregnancy Use of caffeine, tobacco, or alcohol in past 24hours before scan Using sedatives Using medicines that change metabolism ex: INSULIN.
    29. 29. PET-CT FUSIONPET-CT FUSION  FDG PET is a strictly functional modality and lacks anatomic landmarks.  Unless anatomic correlation is available to delineate normal structures, pathologic sites of FDG accumulation can easily be confused with normal physiologic uptake, leading to false-positive or false-negative findings.  Coregistration of PET scans with CT using a combined PET-CT scanner improves the overall sensitivity and specificity of information provided by PET or CT alone .  advantage is ability to correlate findings at two complementary imaging modalities in a comprehensive examination. Hence, PET-CT provides more precise anatomic definition for both the physiologic and pathologic uptake seen at FDG PET
    30. 30. Max coverage during combined study Distance betwn pet and ct scanner
    31. 31. SCANNING TECHNIQUESCANNING TECHNIQUE Nil orally for approximately 4–6 hours avoid caffeinated or alcoholic beverages but can have water during this period. blood glucose level of less than 150 mg/dL is desirable. Avoid strenuous activity to avoid physiologic muscle uptake of FDG water-soluble iodinated contrast media orally for bowel opacification except for head and neck study. 10 mCi injected intravenously Patient activity and speech are limited for 20 minutes immediately following injection Pet study is started 60 mins after injection.
    32. 32. CT TECHNIQUE Contrast material–enhanced helical CT is performed following injection of 125 mL of a contrast medium at a rate of 4 mL/sec by using a power injector . Whole-body PET-CT study scanning begins at the level of the skull base and extends caudally to the level of the symphysis pubis. PET TECHNIQUE The PET scanner is located behind the CT scanner and housed in the same extended-length gantry. PET is performed following the CT study without moving the patient in the caudocranial direction,starting at the thighs to limit artifacts from the FDG metaboliteexcretion into the urinary system
    33. 33. Typical scout image obtained during an FDG PET-CT study. The blue-purple rectangle represents CT coverage during the study, and each overlapping green rectangle represents PET coverage.
    34. 34. INTERPRETATION OF IMAGESINTERPRETATION OF IMAGES PET provides images of quantitative uptake of the radionuclide injected that can give the concentration of radiotracer activity in kilobecquerels per milliliter . Methods for assessment of radiotracer uptake – • visual inspection • standardized uptake value (SUV) • glucose metabolic rate
    35. 35. LIMITATIONS AND ARTIFACTS OF PET-CTLIMITATIONS AND ARTIFACTS OF PET-CT  1.Patient motion may cause confusion as to the correct position of the origin of the detected photon.  Patient motion is minimized by –  carefully instructing patients not to move during the study;  placing them in a comfortable position before the start of the study;  ensuring that they are not taking diuretics, which may otherwise require them to evacuate the bladder during the study;  having patients empty their bladder before the start of the study or catheterizing the bladder. 2.Attenuation (transmission) correction artifacts highly attenuating objects in the path of the CT beam, such as hip prostheses, pacemakers, dental devices, and contrast-enhanced vessels
    36. 36. ADVANTAGES OF PET-CTADVANTAGES OF PET-CT 1. helpful in accurate localization of small areas of increased radiotracer activity that would have been difficult or not possible to localize on PET images alone . 2. helps in distinguishing structures that normally show high metabolic activity from those with abnormally increased activity. 3. PET-CT combines the advantages of the excellent functional information provided by PET and the superb spatial and contrast resolution of CT 4. Finally, attenuation correction for quantitative or semi quantitative assessment of data is possible by using the CT data,
    37. 37. Whole-body PET/MRIWhole-body PET/MRI:: The Future in OncologicalThe Future in Oncological ImagingImaging
    38. 38. PET/MRIPET/MRI: TECHNICAL EVOLUTION: TECHNICAL EVOLUTION  The idea to combine PET and MRI arose as early as the mid 1990s, even before PET/CT was introduced.  The PET/MRI combination requires 3 risky technologic steps that modify state-of-the-art PET and MRI. 1. First, the photomultiplier technology must be replaced with magnetic field–insensitive photodiodes . 2. Second, compact PET detectors must be constructed so that it shouldn't interfere with the field gradients or MR radiofrequency. 3. Finally, the MRI scanner must be adapted to accommodate the PET detectors and to allow simultaneous data acquisition without mutual interference.
    39. 39.  Based on the technologic challenges to combine PET and MRI into a single gantry, Philips and Siemens proposed 2 fundamentally different prototype PET/MRI designs.  In the Siemens prototypes include 4 dedicated brain PET scanners that fit into a standard 3-T clinical MRI scanner. The PET/MRI system, together with a dedicated radiofrequency head coil, allows simultaneous PET/MRI data acquisition of the human brain or body extremities.  Philips developed a PET/MRI design in which the gantries are approximately 2.5 m apart but share a common patient handling system. This implementation does not allow for simultaneous data acquisition and, therefore, results in longer examination times. Scanner DesignScanner Design
    40. 40. CLINICAL POTENTIAL OF PET/MRICLINICAL POTENTIAL OF PET/MRI  It is reasonable to expect that brain PET/MRI will provide new insights in the field of neuroscience and neurologic disorders, such as neuro degeneration, brain ischemia, neuro oncologyor seizures .  It is feasible with current prototypes and future-generation systems to simultaneously study brain function, metabolism, oxygen consumption, and perfusion.  In oncology, an accurate spatial match between PET and MRI data is mandatory for both radiation therapy planning and biopsy guidance.  Combining PET with cardiac MRI may enable detection and differentiation of vulnerable plaques and diseased myocardium.
    41. 41. Advantage of PET/MRI over PET/CT 1. is not associated with significant radiation exposure 2. has a much higher soft tissue contrast. 3. MRI allows for additional techniques - such as angiography, functional MRI ,diffusion ,spectroscopy and perfusion techniques within one single examination.
    42. 42. PHYSIOLOGIC VERSES PATHOLOGIC FDG UPTAKEPHYSIOLOGIC VERSES PATHOLOGIC FDG UPTAKE of FDGof FDG There are several sites of normal physiologic accumulation ofFDG. FDG accumulation is most intense in the cerebralcortex, basal ganglia, thalamus, and cerebellum. The myocardiumexpresses insulin-sensitive glucose transporters, which facilitatethe transport of glucose into muscle. A recent meal often causes intense myocardial FDGuptake because of the associated elevated serum insulin levels Because FDG appears in the glomerular filtrate and, unlike glucose,is not reabsorbed in the tubules, intense FDG activity is seenin the intrarenal collecting systems, ureters, and bladder
    43. 43. The most common areas of normal distribution of FDG include the brain, myocardium, and genitourinary tract. SEMI QUANTITATIVE VALUE- CALCULATION OF INTENSITY OF FDG UPTAKE IN REGION OF INTERST. SUV-5 Indicates five times the average uptake. RISUV - new index, Retention Index SUV after 3 hours. STANDARDISED UPTAKE VALUE
    44. 44. Physiologic FDG uptake
    45. 45. The distribution of FDG within a normal individual (MIP).
    46. 46. Chest •Moderate to high FDG uptake is noted in patients with thymic rebound andshould not be confused with asymmetric uptake due to lymphoma in this location . •In pediatric patients, anatomic correlation is necessary following chemotherapy to differentiate the enlarged thymus from residual or recurrent disease at this location, especially with focal thymic uptake .
    47. 47. Physiologic thymic uptake in a 23-year-old woman with a history of Hodgkin disease of the chest who was referred for posttherapy evaluation.
    48. 48. Low to moderate FDG uptake is noted in the distal esophagus, particularly in patients with gastroesophageal reflux secondary to inflammatory changes. However, high-grade uptake in the same location maybe caused by malignant processes (ie, carcinoma of the distal esophagus, usually associated with morphologic esophageal changes)
    49. 49. Nonneoplastic esophageal uptake in a 21-year-old woman with a history of non-Hodgkin lymphoma
    50. 50. Esophageal adenocarcinoma in a 52-year-old man who was referred for presurgical evaluation.
    51. 51. THE ROLE OF PET/CT IN LUNG CANCER Assessment of the solitary pulmonary nodule (SPN) Staging of non-small cell lung cancer (NSCLC) Assessment of mediastinal lymphadenopathy Identification of distant metastatic disease Detection of recurrent disease
    52. 52. Solitary pulmonary noduleSolitary pulmonary nodule ? Benign or malignant
    53. 53. No activity. Diagnosis: benign bronchocoele Top Tip Approximately 85% of metabolically active pulmonary nodules are malignant. If an FDG positive pulmonary nodule is found, it should be assumed to be malignant until proved otherwise.
    54. 54. Bilateral pulmonary nodules. Diagnosis: metabolically active pulmonary sarcoidosis.
    55. 55. False positive SPN False negative SPN 1.Granulomas BAC 2.Sarcoidosis Scar adenoca 3.Infection carcinoids 4.Adenomas 5.Hamartomas 6.Neurofibromas
    56. 56. Top Tip Without the aid of PET/CT it can be difficult to distinguish active tumor from collapsed lung or necrotic tissue.
    57. 57. Identification of distant metastatic disease Top Tip Evidence suggests that the removal of a solitary adrenal deposit at the time of resection of the lung primary results in an increased life expectancy. Liver, adrenal, brain and bony deposits are common with lung cancer but many of the lesions are undetected in the course of conventional staging
    58. 58. PET/CT IN RADIOTHERAPY PLANNING Patient for radiotherapy. Where does the tumor end and the collapsed lung begin ?
    59. 59. The Role of PET/CT in Lymphoma  Assess response to therapy/residual disease  Identify recurrent disease  Initial diagnosis and staging  Identify suitable sites for biopsy  Disease surveillance  Radiotherapy planning
    60. 60. An example of stage 4 disease. NHL with disease in the mediastinum, neck, and abdomen
    61. 61. ASSESSMENT OF TREATMENT RESPONSE Pretherapy and post therapy studies showing a complete metabolic response to therapy.
    62. 62. Top Tip Brown fat activation can cause confusion and care must be taken to ensure that each area of uptake corresponds to fat. Activated brown fat is seen more commonly in thin individuals during the winter months, but there is also an increased incidence in women and in patients suffering from lymphoma
    63. 63. Intense marrow activation following granulocyte stimulating factor.
    64. 64. Head and Neck Moderate to high FDG uptakeis noticeable in the muscles, including the ocular muscles. may be a potential source of false-positive findings inpatients with malignant head and neck tumors. Contraction-induced FDG uptakein cervical muscles in tense patients can be confused with lymphnode metastasis which constitutes a serious problem in patients with asymmetric muscleuptake due to prior neck dissection.
    65. 65. FDG accumulates in the striated laryngeal muscles in proportion to contractile activity during speech. This phenomenon is a major concern and may lead to false readings in patients with head and neck cancers . Rigorous approach to preventing physiologic FDG uptake in thelaryngeal muscles should be adopted to avoid false-positive findings.
    66. 66. Physiologic laryngeal uptake in a 52-year-old woman with squamous cell carcinoma of the floor of the mouth.
    67. 67. Primary tumor of the larynx in a 45-year-old man with epiglottic carcinoma who was referred for presurgical evaluation.
    69. 69. NEURO-ONCOLOGY Tumor recurrence versus radiation necrosis Diagnosis Grading Monitoring response to therapy Radiotherapy planning Biopsy planning SEIZURE FOCUS IDENTIFICATION STROKE DEMENTIAS OTHER APPLICATIONS Brain injury- vascular, trauma Psychiatry- depression, schizophrenia,anxiety Movement disorders with 18F-dopa Miscellaneous- infection, substance abuse,eating disorders
    70. 70. rere lymphoma Residual glioma rt parietal gbm
    72. 72. High precision Radiation therapy Planning
    73. 73. PET CT PET/CT Biopsy Planning Localizing the most viable tissue in the lesion
    74. 74. Comparison of MRI time-to-peak (TTP) and PET O2 extraction fraction (OEF) images Extensive hypo metabolism of entire brain parenchyma, except thalami & basal ganglia METABOLIC ENCEPHALOPATHY
    75. 75. PET in NeurologyPET in Neurology The Active Human BrainThe Active Human Brain
    76. 76. PET in Brain DisordersPET in Brain Disorders Simultaneous PET/MRI study in Alzheimer disease
    77. 77. Hypo metabolism in left temporal lobe secondary to epilepsy
    78. 78. Abdomen and Pelvis  Moderate to highFDG uptake is visible in the muscles that contribute to breathingin patients with chronic obstructive pulmonary disease.  due todifficulty in breathing and use of accessory muscles to facilitate breathing.  In addition, due to an imbalance between oxygen supplyand increased demand, the decrease in oxygen delivery causesa switch to anaerobic metabolism.  Hence, the increaseduptake seen in the diaphragmatic cruces may be the result of accentuated abdominal breathing effort and the anaerobic metabolismthat leads to increased FDG uptake similar to the physiologicalterations in cancer cells.  Any disease process involving theceliac or perigastric lymph nodes (eg, lymphoma, nodal metastaticdisease) can be difficult to interpret in patients with diaphragmaticuptake, especially in the posttherapy setting.
    79. 79. Physiologic diaphragmatic uptake in a 49-year-old woman with a history of abdominal lymphoma and severe COPD who was referred for posttherapy follow-up.
    80. 80. Low to moderate uptake is usually observed in the stomach. Focal and irregular uptake in the stomachis usually due to a malignant process; nevertheless, local gastritiscannot be excluded with certainty without the help of CT.
    81. 81. Physiologic gastric uptake in a 52-year-old man with colorectal cancer who had undergone surgical tumor resection.
    82. 82. Gastric cancer in a 59-year-old woman
    83. 83. The importance of FDG PET in the evaluation of colorectal canceris well established. Both small and large bowel may demonstratevarying degrees of FDG uptake, usually with a diffuse and linearpattern. However, focal physiologic uptake is not an uncommon finding in short segments of the bowel. UnlessCT correlation is available, the configuration of uptake in thesecases may be indistinguishable from malignant processes .
    84. 84. Adenocarcinoma of the cecum in a 77-year-old man.
    85. 85. Gallbladder uptake of FDG is not a common finding. When activity is observed in this anatomic location, choleductalcancer, adenocarcinoma of the gallbladder, and primary or metastaticdisease of the liver should be considered in the differentialdiagnosis. CT correlation is most helpful in delineatinganatomic landmarks and distinguishing a benign gallbladder variantfrom malignant lesions.
    86. 86. Chronic cholecystitis in a patient with papillary thyroid cancer who underwent thyroidectomy
    87. 87. Liver metastasis in a 55-year-old man with rectal adenocarcinoma.
    88. 88. Unlike glucose, FDG is not reabsorbed by the renal tubules afterfiltration. Thus, significant FDG accumulation is seen in theintrarenal collecting system and renal pelvis. This accumulationmay interfere with the identification of renal parenchymal orpelvic urothelial tumors. However, anatomicinformation provided by CT allows proper assessment and characterizationof renal masses
    89. 89. Renal cell carcinoma in a 60-year-old woman
    90. 90. Focal FDG accumulation in the ureters is a common finding dueto the pooling of radiotracer in the recumbent patient. althoughthe intensity and location of uptake usually allow accurateidentification of the ureters in patients with abdominal malignancies, this finding can be misdiagnosed as pelvic lymph node metastasisor nodal lymphoma.
    91. 91. Physiologic uptake in the renal pelvis in a 66-year-old man with a history of colorectal cancer .
    92. 92. There is usually no FDG accumulation in the uterus, althoughfocal FDG uptake in the uterus during menstruation has beendescribed. can beattributed to heavy bleeding or to necrotic endometrial epitheliumdue to sudden reduction of estrogen and progesterone levelsat the end of the secretory phase of the menstrual cycle. Itmay not be possible to differentiate this uptake pattern fromuterine carcinoma, even with the help of PET-CT . However, FDG uptake is usually more irregular, diffuse, and extensive in uterine cancer .  
    93. 93. Physiologic uterine uptake in a 40-year-old woman with a history of lymphoma who was referred for posttherapy evaluation.
    94. 94. Endometrial cancer in a 66-year-old woman.
    95. 95. Cardiac PET andCardiac PET and Myocardial perfusion ImagingMyocardial perfusion Imaging  Rb Distributed in the myocardium depending on the regional blood flow Rb delivery limited to ischemic or underperfused areas These areas will appear as defect on initial images On delayed images(2-4hrs) post inj Defects resolves due to redistribution which reflects not only eventual accumulation of Rb in viable ischemic zones but release & washout from normally perfused area (Areas of myocardial infarction or fibrosis present as permanent defects due to lack of perfusion)
    96. 96. CARDIAC PET and PET CT IMAGING The stress images show a severe perfusion defect throughout the anterolateral wall that is completely reversible at rest
    97. 97.  The first heart has a mycardial infarction. The arrows point to damaged areas (‘dead’ tissue).Therefore it is assumed that the patient will not benefit from heart surgery.  The second heart is normal Example: Myocardial Viability
    98. 98. PET IN INFLAMMATORY CONDITIONS Hepatic and splenic uptake of FDG are generally low grade and diffuse In the setting of infection, splenic uptake can be intense.
    99. 99. Acquired Immuno-deficiency Syndrome. Till now, gallium imaging radionuclide imaging - study of choice in evaluating opportunistic infections in AIDS patients. FDG – PET – helpful in many CNS conditions in AIDS patients. Lymphoma and toxoplasmosis are frequent CNS complications – not always distinguishable at CT and MRI. CNS LYMPHOMA- Highly metabolically active. TOXOPLASMOSIS- metabolically inactive.
    100. 100. FDG PET of Infection and Inflammation1 Toxoplasmosis in an AIDS patient Acquired Immuno-deficiency Syndrome
    101. 101. CNS lymphoma in a different AIDS patientCNS lymphoma in a different AIDS patient Acquired Immuno-deficiency Syndrome
    103. 103. 3.OSTEOMYELITIS Increased metabolic activity in inflammation results in increased FDG uptake. Also occur in a. inflammatory arthritis b. acute fractures, c. normally healing bone after surgery.
    104. 104. Differentiation between inflammatory and malignant lesions.  Traditionally, a single time point SUV of 2.0–3.0 hasbeen proposed as the optimal threshold for separating malignantfrom benign lesions.  With the exception of granulomatous lesions- malignant lesions shows increased SUV values on delayed images i.e., increased RI SUV ( RETENTION INDEX SUV ).  DUAL TIME FDG PET imaging at two intervals appears promising now. Lesions with decreased SUV s over time are likely to have a benign etiology. Malignant lesions tend to have increase in SUV over time.
    105. 105. PET vs. SPECTPET vs. SPECT PET have superior sensitivity and resolution Greater flexibility of incorporating positron labels into biomolecules PET is more expensive and requires the presence of an onsite cyclotron
    106. 106. PEMPEM  Positron Emission Mammography  PEM is a specialized & improved form of PET for imaging breasts and other small body parts.  Camera and detectors are closer to the area affected with cancer which produces a very sharp detailed image of tumors and cancerous tissue.  Can see cancers as small as 1.5 – 2mm about the width of a grain of rice.  Also allows for the earlier detection of elusive cancers such as DCIS (ductal carcinoma in situ).
    107. 107. PEMPEM
    108. 108. Breast PET MRIBreast PET MRI Schematic diag of pet insert and mri coil
    109. 109. Understand the differences between whole-body PET and PEM Spatial Resolution better spatial resolution (1-2 mm vs. 5-10 mm). This comes at the cost of field-of-view Photon-Detection Sensitivity  •Closer proximity of PEM detectors increases geometric sensitivity  Allows lower dose/faster imaging/longer uptake time
    110. 110. differences between mammography and PEM  Transmission vs. Emission Imaging  Anatomical vs. Functional Imaging  Planar vs. Tomosynthesis (or Tomographic)  •Planar is single projection view with considerable tissue overlap  •Tomosynth./tomographic is 3-dimensional volumetric image  Utilities, cost, dose
    111. 111. CONCLUSIONCONCLUSION Detection of coincidence photons emitted during positron annihilationis the key to PET imaging, whereas accurate coregistration ofthis quantitative/functional information with the CT data isthe key to successful PET-CT imaging. Specific attention topatient preparation, data acquisition, data reconstruction,and image interpretation is crucial to obtaining high-qualityPET-CT images. Fusion of the anatomic and functional imagesby using a dedicated PET-CT /Pet mri scanner is exploited for optimalresults required in the management of complex clinical scenariosfaced by our clinical colleagues. Having witnessed an impressive technologic development of PET detector technology, first PET/MRI prototype systems, and MRI-based PET attenuation correction, as well as encouraging clinical and specifically preclinical PET/MRI results, we now seek opportunities to translate these technologic advances into clinical benefits
    112. 112. CT/PET/MRI-Anatomical + Functional imaging. 18F-FDG-Increase glucose utilisation in malignancies. Oncology,Neurology ,Cardiology Diagnosis. Staging. Restaging. Monitoring response to therapy. Guided biopsy. Radiotherapy planning
    113. 113. THANK YOUTHANK YOU new ideas make work interestingnew ideas make work interesting